Pathology, imaging, and treatment of cardiac tumours

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Cardiac tumours include a wide array of both neoplastic and non-neoplastic entities. Cardiac tumours are often found incidentally during imaging by ultrasonography, CT, or MRI. In this Review, Maleszewiski and colleagues discuss the clinical presentation, imaging characteristics, pathological characteristics, and treatment of these lesions.

Related collections

Most cited references 77

Record: found
Abstract: found
Article: not found

Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study.

Nicolas Penel, Binh Nguyen Bui, Jacques-Olivier Bay … (2008)

The objective of this phase II trial was to assess the efficacy and toxicity of weekly paclitaxel for patients with metastatic or unresectable angiosarcoma. Thirty patients were entered onto the study from April 2005 through October 2006. Paclitaxel was administered intravenously as a 60-minute infusion at a dose of 80 mg/m(2) on days 1, 8, and 15 of a 4-week cycle. The primary end point was the nonprogression rate after two cycles. The progression-free survival rates after 2 and 4 months were 74% and 45%, respectively. With a median follow-up of 8 months, the median time to progression was 4 months and the median overall survival was 8 months. The progression-free survival rate was similar in patients pretreated with chemotherapy and in chemotherapy-naïve patients (77% v 71%). Three patients with locally advanced breast angiosarcoma presented partial response, which enabled a secondary curative-intent surgery with complete histologic response in two cases. One toxic death occurred as a result of a thrombocytopenia episode. Six patients presented with grade 3 toxicities and one patient presented with a grade 4 toxicity. Anemia and fatigue were the most frequently reported toxicities. Weekly paclitaxel at the dose schedule used in the current study was well tolerated and demonstrated clinical benefit.

0 comments Cited 160 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

MR imaging of cardiac tumors and masses: a review of methods and clinical applications.

David B Herzog, Manish Motwani, John Greenwood … (2013)

Cardiac masses are usually first detected at echocardiography. In their further evaluation, cardiac magnetic resonance (MR) imaging has become a highly valuable technique. MR imaging offers incremental value owing to its larger field of view, superior tissue contrast, versatility in image planes, and unique ability to enable discrimination of different tissue characteristics, such as water and fat content, which give rise to particular signal patterns with T1- and T2-weighted techniques. With contrast material-enhanced MR imaging, additional tissue properties such as vascularity and fibrosis can be demonstrated. MR imaging can therefore contribute to the diagnosis of a cardiac mass as well as be used to detail its relationship to other cardiac and extracardiac structures. These assessments are important to plan therapy, such as surgical intervention. In addition, serial MR studies can be used to monitor tumor regression after surgery or chemotherapy. Primary cardiac tumors are very rare; metastases and pseudotumors (eg, thrombus) are much more common. This article provides an overview of cardiac masses and reviews the optimal MR imaging techniques for their assessment.

0 comments Cited 126 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated With CDK4 Inhibitor Palbociclib: A Phase 2 Clinical Trial.

Mark A. Dickson, Gary K. Schwartz, Mary Keohan … (2016)

More than 90% of well-differentiated or dedifferentiated liposarcomas (WD/DDLS) have CDK4 amplification. The selective CDK4 and CDK6 inhibitor palbociclib inhibits growth and induces senescence in liposarcoma cell lines and xenografts. Our prior phase 2 study demonstrated that treatment with palbociclib (200 mg daily for 14 days every 21 days) resulted in clinical benefit in WD/DDLS but moderate hematologic toxic effects. It is important to understand whether palbociclib at a new dose and schedule-125 mg daily for 21 days every 28 days-results in clinical benefit and manageable toxic effects.

0 comments Cited 119 times – based on 0 reviews      Review now

Bookmark

All references

Author and article information

Journal

Title: Nature Reviews Cardiology

Abbreviated Title: Nat Rev Cardiol

Publisher: Springer Nature

ISSN (Print): 1759-5002

ISSN (Electronic): 1759-5010

Publication date Created: April 24 2017

Publication date (Print): April 24 2017

Volume:

Issue:

Article

DOI: 10.1038/nrcardio.2017.47

PubMed ID: 28436488

SO-VID: 28554da8-f119-40b2-b4ae-28ee361bdec0

History

Data availability:

Comments

Comment on this article

scite_

Cited by 46

See all cited by

Most referenced authors 1,111

See all reference authors

Pathology, imaging, and treatment of cardiac tumours

Read this article at

Abstract

Related collections

Electron Channelling Contrast Imaging (ECCI)

Most cited references 77

Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study.

MR imaging of cardiac tumors and masses: a review of methods and clinical applications.

Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated With CDK4 Inhibitor Palbociclib: A Phase 2 Clinical Trial.

Author and article information

Journal

Article

History

Comments

Comment on this article

Similar content 407

Cited by 46

Most referenced authors 1,111